In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Small-cell lung cancer represents a highly aggressive neuroendocrine subtype of lung cancer. In distant metastatic or ...